Jaguar health announces fda activation of third-party investigational new drug (ind) application for evaluation of crofelemer for treatment of uncontrolled diarrhea in patient with short bowel syndrome (sbs)

Napo pharmaceuticals, a jaguar health company and the manufacturer of crofelemer, is supporting this physician-generated ind san francisco, ca / accesswire / august 1, 2023 / jaguar health (nasdaq:jagx) ("the company") today announced the activation by the u.s. food and drug administration (fda) of a physician-requested investigational new drug (ind) application to evaluate crofelemer for treatment of uncontrolled diarrhea in a patient with short bowel syndrome (sbs), a rare and complex condition characterized by diarrhea and/or severe malabsorption of fluids and nutrients. napo pharmaceuticals, a jaguar company, is supporting this investigator-initiated trial of crofelemer, the company's oral anti-diarrheal prescription drug.
JAGX Ratings Summary
JAGX Quant Ranking